I'm the Spike Man
Release time:
2020-08-14
I am the peak person
■ Jinxi Pharmaceutical Factory Wang Meiqin
This year 7# November, my inauguration peak just reached the 13th anniversary of 22.
The past is like turning the pages of a book, but the title page is always unforgettable. 22 years ago, I was transferred from the post of kindergarten teacher to peak work. After a week of strict military training, I was officially assigned to Jinhua Cement Factory. I remember that when I reported for work on the first day, I was really surprised by the sight in front of me: although the floor of the whole factory was clean, there was thick cement ash on the roof of the factory building; Vehicles transporting raw materials and cement in and out of the factory were busy, and dust flying after the trucks. Workers wore gray work clothes, hoods and masks to walk through the "fog; the rumble of the mill in the raw material workshop was deafening... Everything was like a battlefield filled with smoke. Is this where I will work in the future? Looking back on the neat, fresh, bright and spacious classroom, facing a group of innocent and lovely children, it is a world of difference. To tell the truth, at that time I lingered, hesitated, and even had the idea of resigning. Fortunately, after the patient guidance of the leaders in thought and the enthusiastic help of the old colleagues in their work, I began to calm down and understand the cement industry from a more rational point of view, so as to gradually adapt to the new environment and integrate into it. I have also personally experienced the progress and changes in the process of enterprise development, and all the puzzles have been slowly dispelled with time. The year before last, I came to the original site of Jinhua Cement Plant again. The old scene is no longer there. Only a majestic Temple of the Wise stands in front of me, but in my mind, this will always be the base for the older generation of peak people to work hard. It will always rely on cattle to pull carts and trolleys to create today's top 100 enterprises. This is my pride and pride as a spike!
In 2000 , I was transferred to the sales department of Jianfeng Pharmaceutical due to work needs. In a training session of the department, Jiang Xiaomeng, the general manager of the pharmaceutical company at the time, said a passage that is still fresh in my memory: "We do sales, and we cannot blindly market our products. We must first learn to be human, because our conversation, As it represents the corporate image and product quality. Only when customers have a deep understanding of your personality can they recognize your products. The word" human "is easy to write and not easy to do. Only by constantly improving and enriching yourself in future work and study can we receive unexpected results." His words pointed out the work direction for our sales staff, and we also earnestly implemented this principle in our future work, doing things seriously and being a down-to-earth person. Nowadays, Jianfeng Pharmaceutical products sell well all over the country. It is precisely because we Jianfeng people adhere to the concept of "people-oriented, scientific management, pursuit of excellent quality, and benefit human society", which has created brilliance one by one.
From 2007 to now, my position is "Commissioner of Methoxime". I clearly remember that at that time, when I took over the related work of cefmenoxime for injection, the sales volume of methyl oxime was "sesame blossoming steadily higher", and the situation was gratifying. With the continuous improvement of production technology, cefmenoxime hydrochloride for micronized injection was added in 2009 4 , which pushed the sales volume to a new peak and appeared in short supply. For three consecutive years from 2010 to 2012 , the average annual sales of individual products exceeded 100 million yuan, creating considerable benefits for the company.
The development and growth of Jianfeng Pharmaceutical is also the epitome of Jianfeng Group's continuous outstanding achievements. In the days to come, we peak people will join hands, Do not forget your initiative mind, keep in mind our mission and continue to advance towards the grand goal of "one hundred years peak.
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page